On December 16, 2024 Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, reported the submission of its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for its MDG1015 program for the treatment of advanced gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma in the phase 1 clinical trial EPITOME1015-I (Press release, MediGene, DEC 16, 2024, View Source [SID1234649140]). The CTA submission follows the Company’s receipt of the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for EPITOME1015-I earlier this year.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
EPITOME1015-I consists of a dose escalation followed by an expansion segment and aims to assess safety, feasibility and preliminary efficacy of MDG1015 in multiple solid tumor indications.
"We are delighted to announce the submission of the CTA for MDG1015. This milestone is a significant step forward in the development of our differentiated cell therapy. The extensive experience of European clinical sites provides an ideal environment for this trial. The robust infrastructure and strong network of clinical investigators will facilitate efficient patient recruitment once funding is secured, which will enable us to then rapidly progress toward bringing this potentially transformative therapy to patients in need," said Selwyn Ho, CEO at Medigene AG.
MDG1015 is a first-in-class, third generation T cell receptor engineered T cell (TCR-T) therapy targeting the cancer-testis antigen New York esophageal squamous cell carcinoma 1 / L Antigen Family Member-1a (NY-ESO-1/LAGE-1a) in the context of human leukocyte antigen (HLA)-A*02 with a natural and optimal affinity 3S (specific, sensitive and safe) TCR. The TCR-T cells are further armored and enhanced by the addition of the proprietary costimulatory switch protein (CSP) PD1-41BB and have demonstrated significantly enhanced anti-tumor activities against tumor cells expressing varying levels of PD-L1, one of the most immunosuppressive signals emanating from the solid tumor microenvironment. Importantly, compared to first generation TCR-T therapies, MDG1015 will be manufactured with a short, 6-day cell expansion period, leading to younger, fitter cells, with the potential for a markedly reduced number of cells required during dosing and a shorter vein-to-vein time for patients of approximately 20 days. This has also resulted in a drug product with an almost pure CD8+ population and with a very high proportion of cells with stemness-like qualities (~95%) that could lead to improved durability of response, greater efficacy and reduced adverse events.